Earlier post-operative hypocortisolemia may predict durable remission from Cushing’s disease

Natasha Ironside1,2, Gregoire Chatain3, David Asuzu1,4, Sarah Benzo1, Maya Lodish5, Susmeeta Sharma6, Lynnette Nieman7, Constantine A Stratakis5, Russell R Lonser8 and Prashant Chittiboina1,3

1Surgical Neurology Branch, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland, USA, 2Department of Neurosurgery, Auckland City Hospital, Auckland, New Zealand, 3Neurosurgery Unit for Pituitary and Inheritable Diseases, National Institute of Neurological Diseases and Stroke, Bethesda, Maryland, USA, 4Yale School of Medicine, New Haven, Connecticut, USA, 5Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA, 6Pituitary Endocrinology Section, MedStar Washington Hospital Center, Washington, District of Columbia, USA, 7National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA, and 8Department of Neurological Surgery, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA

Abstract

Context: Achievement of hypocortisolemia following transsphenoidal surgery (TSS) for Cushing's disease (CD) is associated with successful adenoma resection. However, up to one-third of these patients recur.

Objective: We assessed whether delay in reaching post-operative cortisol nadir may delineate patients at risk of recurrence for CD following TSS.

Methods: A retrospective review of 257 patients who received 291 TSS procedures for CD at NIH, between 2003 and 2016. Early biochemical remission (serum cortisol nadir ≤5 μg/dL) was confirmed with endocrinological and clinical follow-up. Recurrence was detected by laboratory testing, clinical stigmata or medication dependence during a median follow-up of 11 months.

Results: Of the 268 unique admissions, remission was recorded in 241 instances. Recurrence was observed in 9% of these cases with cortisol nadir ≤5 µg/dL and 6% of cases with cortisol nadir ≤2 µg/dL. The timing of hypocortisolemia was critical in detecting late recurrences. Morning POD-1 cortisol <3.3 µg/dL was 100% sensitive in predicting durable remission and morning POD-3 cortisol ≥18.5 µg/dL was 98.6% specific in predicting remote recurrence. AUROC analysis revealed that hypocortisolemia ≤5 µg/dL before 15 h (post-operative) had 95% sensitivity and an NPV of 0.98 for durable remission. Serum cortisol level ≤2 µg/dL, when achieved before 21 h, improved sensitivity to 100%.

Conclusions: In our cohort, early, profound hypocortisolemia could be used as a clinical prediction tool for durable remission. Achievement of hypocortisolemia ≤2 µg/dL before 21 post-operative hours appeared to accurately predict durable remission in the intermediate term.

Introduction

Left untreated, chronically elevated endogenous hypercortisolemia resulting from Cushing’s disease (CD) is associated with significant morbidity and mortality (1, 2). Transsphenoidal surgery (TSS) for resection of corticotropinoma is the first-line treatment, offering the potential for remission in 77–98% of cases (2, 3, 4, 5, 6, 7). Successful corticotropinoma resection leads to transient post-operative adrenocorticotropic (ACTH) and
cortisol deficiency, due to suppression of the remaining normal pituitary corticotrophs by long-standing hypercortisolemia (8, 9). Given the short serum half-lives of ACTH and cortisol, a rapid drop in levels would be expected during the immediate post-operative period (10, 11). As demonstrated by the faster rate of decline in serum levels achieved by total hypophysectomy, when compared to subcapsular resection, there is evidence to suggest that the residual corticotrophs do remain functional following complete removal of the ACTH-secreting adenoma (12).

In the post-operative setting, failure to achieve hypocortisolemia is thought to reflect the presence of residual tumor cells (13, 14). Therefore, serum cortisol has become a well-established biochemical marker of early surgical remission, with rates reported to range from 65 to 98% at experienced centers (15, 16, 17, 18, 19). However, despite early remission, recurrence has been observed in 2–35% of these cases, occurring up to thirty years post-operatively (12, 15, 16, 18, 20, 21, 22). Because pituitary adenomas are monoclonal in origin, disease recurrence is thought to result from microscopic residual tumor cells left at the adenoma margin or unrecognized dural invasion along the wall of the cavernous sinus (1, 13, 23, 24). Early re-operation has been shown to achieve remission in the majority of these patients requiring further treatment (13, 15, 25, 26). This highlights the possibility that post-operative cortisol values may reflect the extent of microscopic resection.

In an attempt to define the subset of patients at high likelihood of recurrence, early identification of surgical success has been the focus of several recent studies (17, 19, 20, 21, 27, 28, 29, 30). The technique of pseudocapsular resection, hypothesized to achieve complete tumor resection, has been associated with a rapid rate of post-operative cortisol decline (12). More recently, normalized early post-operative values (NEPV), capitalizing on the potential for endoscopic TSS to act as an endogenous corticotrophin-releasing hormone (CRH) stimulation test, have been shown to improve accuracy in predicting early non-remission (30).

We hypothesized that the slope of serum cortisol decline in the immediate post-operative period may be used as a predictive biomarker for the completeness of tumor resection in ACTH-secreting pituitary adenoma. This may aid in the identification of patients who could benefit from enhanced biochemical follow-up to prevent disease relapse.

Subjects and methods

Data from 328 patients who received 364 consecutive sublabial transsphenoidal surgeries for adrenocorticotrophic (ACTH)-secreting pituitary adenomas by a team of surgeons (EHO, RRL and PC) from December 2003 until July 2015 was retrospectively reviewed. All operations took place at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD under research protocol NIH ID 03-N-0164 (clinicaltrials.gov identifier NCT00060541). Written informed consent was obtained from each patient for study participation, and the study was performed within the clinical and ethical guidelines of the Combined Neurosciences Institutional Review Board of the NIH.

Diagnosis of Cushing’s disease

The work-up for CD has previously been described and is summarized below (31, 32, 33, 34, 35). Cushing’s syndrome was confirmed on the basis of elevations of at least two of the following laboratory tests: late night salivary cortisol, 24-h urine free cortisol or low-dose dexamethasone suppression testing (1 mg overnight or 2 mg over 48 h, normal cortisol <1.8 μg/L) (1, 35). Supplemental diagnostic testing included midnight serum cortisol and morning cortisol following 8 mg overnight dexamethasone suppression testing (HDDST) (36, 37).

A diagnosis of CD was made in patients with ACTH-dependent hypercortisolism with at least one of the following: response of serum cortisol or ACTH to ovine corticotropin-releasing hormone (oCRH) stimulation testing, identification of adenoma on magnetic resonance imaging (MRI) of the pituitary or a central-to-peripheral ACTH gradient during inferior petrosal sinus sampling (IPSS) (33, 34, 38). Pituitary microadenomas were detected as hypoattenuated regions within the sella on early, post gadolinium contrast 3D gradient recalled echo imaging (39, 40, 41). IPSS was performed in patients where HDDST, oCRH and pre-operative MRI were not concordant (26).

The presence, size and location of lesions were recorded on the pre-operative MRI report. Surgical findings, denoting the size and location of the adenoma, were recorded on a graphical post-operative record of the pituitary gland. The presence and location of ACTH-positive pituitary adenoma on histopathology was noted. Concordance was referenced to imaging and/or surgical findings.
The biochemical assays and imaging modalities used in this study have previously been described in the literature (7, 30, 42).

**Post-operative outcomes**

Serum cortisol levels were routinely obtained at 6-h intervals from post-operative day 0 (POD-0) through day 3 (POD-3). The initial post-operative serum cortisol was obtained at 12:00 h POD-0 or 18:00 h depending upon the time of completion of surgery. After POD-3, daily morning cortisol levels were obtained until post-operative day 10 (POD-10) during their inpatient stay or until patient discharge (27, 30).

Early biochemical remission was assigned by detecting nadir serum cortisol level of <5 µg/dL or <2 µg/dL by POD-10, prior to administration of exogenous glucocorticoids and sustained hypocortisolemia necessitating glucocorticoid replacement (33). All patients in whom this was not achieved (persistent CD) were excluded from further analysis. For patients undergoing early repeat TSS for persistent CD, cortisol values obtained after the final, successful TSS procedure were included for analysis.

Clinical stigmata of Cushing’s syndrome (recurrence of height arrest in children, weight gain, hypertension, plethora), biochemical evidence of hypocortisolemia (24 h urinary free cortisol, diurnal serum cortisol and ACTH or more recently, salivary cortisol), need medical therapy targeting Cushing’s syndrome (ketoconazole initiation to suppress serum cortisol) or requirement for further surgical management formed the criteria for assigning recurrence.

**Statistical analysis**

Patients were divided into remission and recurrence groups for statistical analysis. Baseline clinical characteristics were presented as percentages or as means with standard deviations. Binomial variables were compared using two sample tests of proportions or two sample $T$-tests with unequal variance (43), while categorical variables were compared using chi-square and Fisher’s exact tests, where appropriate. One-way ANOVA and Tukey post hoc tests were used for the comparison of proportions of means, reported as mean difference (MD). Kaplan–Meier analysis, using cortisol nadir as the survival event, was conducted to compare the time to reach post-operative cortisol nadir ($\leq 5$ µg/dL or $\leq 2$ µg/dL) between remission and recurrence groups. Statistical significance was assessed using the log-rank test (39). Additionally, CD recurrence was used as a survival event to distinguish the ability of cutoffs to predict durable remission. Predictors of recurrence were identified with logistic regression, using recurrence as the dependent variable and evaluated for quality of fit using areas under the receiver-operating characteristic curve (AUROC). Score cutoffs were chosen for sensitivity and specificity analysis after AUROC, confirmed using 2×2 tables. Standard errors were calculated by the DeLong method (40). $P$ values $<0.05$ two-tailed were considered statistically significant. GraphPad Prism 6.0 software was used for statistical figures (GraphPad Software). Statistical analyses were performed using SPSS, version 24.0 (IBM Corporation).

**Results**

Two hundred and fifty seven patients receiving 291 TSS procedures were included in this study. The rest were excluded due to lack of adequate post-operative laboratory values or due to inadequate follow-up. Twenty-three procedures were early repeat TSS surgeries for persistent CD; resulting in 268 unique admissions. Of these, remission was achieved in 241 (90%) patients, with post-operative cortisol nadir $\leq 5$ µg/dL within 10 post-operative days. Meanwhile, in 222 (82.8%) hypocortisolemia of $\leq 2$ µg/dL was detected within 10 post-operative days. Only the 241 instances with remission and hypocortisolemia $\leq 5$ µg/dL were included for further analysis. Patients were followed up for a mean of 14 months (median 7 months, interquartile range 1–17 months, range 1–150 months).

**Recurrence**

At the last follow-up, recurrence was observed in 8.7% ($n=21/241$) of cases achieving cortisol nadir $\leq 5$ µg/dL and in 5.9% ($n=13/222$) of cases achieving cortisol nadir $\leq 2$ µg/dL. Of the 19 cases achieving cortisol nadir $\leq 5$ µg/dL but not $\leq 2$ µg/dL, 42% ($n=8$) recurred. Recurrence occurred at a median of 11.86±20.52 months. There was a statistically significant difference in the rate of recurrence between the three groups (ANOVA $F$ statistic (2, 479)=1551, $P<0.001$). Upon post hoc analysis, the difference remained significant ($P=(0.05/3)=0.0167$, for exploratory analysis) between each of the three nadir cutoff values of $\leq 5$ µg/dL (A), $\leq 2$ µg/dL (B) and 2.1–5 µg/dL (C) (A vs B MD=0.03, $P<0.001$; A vs C MD=−0.33, $P<0.001$; B vs C MD=−0.36, $P<0.001$).

Patients did not differ significantly in BMI, gender, age or race between the durable remission
and recurrence groups. As expected (41), the proportion of MRI-positive adenomas (n=239); intra-operatively visualized macroscopic adenomas (n=233; pathology-confirmed adenomas (n=232) and location-concordance between imaging and histopathological findings (n=239) did not differ significantly between the two groups. The rate of location-concordance between imaging and surgical findings (n=153) was lower in the recurrence group (57 vs 42%, \( P=0.026 \)), suggesting that adenomas that were detected well both with imaging, during surgery tended to recur less frequently (Table 1).

**Early post-operative serum cortisol analysis**

Survival analysis of time to reach nadir serum cortisol revealed a statistically significant difference between the durable remission and recurrence groups in patients achieving nadir serum cortisol \( \leq 5 \mu g/dL \) (\( P=0.002 \)) (Fig. 1A). Despite a statistically significant difference observed on log-rank test, the median time to reach nadir cortisol \( \leq 5 \mu g/dL \) was 42h in both the remission and recurrence groups. No difference in time to reach nadir cortisol was found in patients within subgroups nadir \(< 2 \mu g/dL \) (Fig. 1B) or nadir 2–5 \( \mu g/dL \) (Fig. 1C).

To assess the effect of immediate cortisol decline on rates of recurrence, we performed a subgroup analysis on patients with available early (<42h) post-operative laboratory values (n=128). This analysis enabled the exclusion of patients who had their first serum cortisol recorded at \( \geq 42h \) but who may have achieved nadir cortisol prior to his time. The median time to reach cortisol nadir \( \leq 5 \mu g/dL \) was significantly different between the two groups (18h vs 42h \( P=0.004 \)) (Fig. 1D and E). These findings suggest that patients who have eventual recurrence may have a slight delay in serum cortisol nadir following TSS. The findings also suggest that early serum cortisol (<42h) is critical to detect this slight delay.

**Table 1** Univariate logistic regression analysis identifying predictors of recurrence in patients achieving early biochemical remission. Remission was defined as cortisol nadir \( \leq 5 \mu g/mL \) by POD-10. Measures of association are represented as odds ratio with corresponding \( P \) values. Accounting for potential confounding variables of age, gender, BMI and ethnicity, adjusted odds ratio with corresponding \( P \) values are presented.

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR</th>
<th>95% CI</th>
<th>s.e.</th>
<th>( P ) Value</th>
<th>Adj OR</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>1.023</td>
<td>0.99, 1.06</td>
<td>0.016</td>
<td>0.150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>1.013</td>
<td>0.95, 1.08</td>
<td>0.031</td>
<td>0.663</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>0.737</td>
<td>0.26, 2.10</td>
<td>0.534</td>
<td>0.568</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>1.519</td>
<td>0.60, 3.84</td>
<td>0.474</td>
<td>0.378</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>0.585</td>
<td>0.18, 1.87</td>
<td>0.594</td>
<td>0.366</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>0.320</td>
<td>0.06, 1.65</td>
<td>0.837</td>
<td>0.173</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Perioperative outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI positive</td>
<td>1.030</td>
<td>0.38, 2.78</td>
<td>0.506</td>
<td>0.954</td>
<td>0.877</td>
<td>0.812</td>
</tr>
<tr>
<td>Visualized intra-operatively</td>
<td>0.664</td>
<td>0.15, 3.00</td>
<td>0.770</td>
<td>0.595</td>
<td>0.683</td>
<td>0.637</td>
</tr>
<tr>
<td>Imaging/resection concordance</td>
<td>3.758</td>
<td>1.17, 12.11</td>
<td>0.597</td>
<td>0.027*</td>
<td>7.010</td>
<td>0.006**</td>
</tr>
<tr>
<td>Pathology positive</td>
<td>1.958</td>
<td>0.61, 6.34</td>
<td>0.600</td>
<td>0.262</td>
<td>2.196</td>
<td>0.238</td>
</tr>
<tr>
<td>Imaging/pathology concordance</td>
<td>2.097</td>
<td>0.85, 5.16</td>
<td>0.460</td>
<td>0.107</td>
<td>1.039</td>
<td>0.074</td>
</tr>
<tr>
<td><strong>Cortisol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>00:00h POD-0</td>
<td>0.971</td>
<td>0.94, 1.01</td>
<td>0.018</td>
<td>0.109</td>
<td>0.962</td>
<td>0.068</td>
</tr>
<tr>
<td>18:00h POD-0</td>
<td>0.974</td>
<td>0.94, 1.01</td>
<td>0.017</td>
<td>0.116</td>
<td>0.970</td>
<td>0.135</td>
</tr>
<tr>
<td>00:00h POD-1</td>
<td>0.970</td>
<td>0.94, 1.01</td>
<td>0.017</td>
<td>0.075</td>
<td>0.959</td>
<td>0.061</td>
</tr>
<tr>
<td>06:00h POD-1</td>
<td>0.933</td>
<td>0.89, 0.98</td>
<td>0.026</td>
<td>0.007**</td>
<td>0.904</td>
<td>0.002**</td>
</tr>
<tr>
<td>12:00h POD-1</td>
<td>0.907</td>
<td>0.82, 1.00</td>
<td>0.049</td>
<td>0.043*</td>
<td>0.873</td>
<td>0.040*</td>
</tr>
<tr>
<td>18:00h POD-1</td>
<td>0.889</td>
<td>0.81, 0.98</td>
<td>0.048</td>
<td>0.014*</td>
<td>0.887</td>
<td>0.028*</td>
</tr>
<tr>
<td>18:00h POD-2</td>
<td>0.894</td>
<td>0.78, 1.03</td>
<td>0.072</td>
<td>0.119</td>
<td>0.847</td>
<td>0.072</td>
</tr>
<tr>
<td>00:00h POD-3</td>
<td>1.023</td>
<td>0.89, 1.18</td>
<td>0.073</td>
<td>0.752</td>
<td>1.030</td>
<td>0.748</td>
</tr>
<tr>
<td>06:00h POD-3</td>
<td>0.959</td>
<td>0.92, 1.00</td>
<td>0.022</td>
<td>0.062</td>
<td>0.959</td>
<td>0.062</td>
</tr>
<tr>
<td>12:00h POD-3</td>
<td>0.900</td>
<td>0.82, 1.00</td>
<td>0.050*</td>
<td>0.036*</td>
<td>0.882</td>
<td>0.130</td>
</tr>
<tr>
<td>18:00h POD-3</td>
<td>0.981</td>
<td>0.93, 1.04</td>
<td>0.028</td>
<td>0.487</td>
<td>1.010</td>
<td>0.842</td>
</tr>
<tr>
<td>NEPV cortisol</td>
<td>0.931</td>
<td>0.87, 0.99</td>
<td>0.033*</td>
<td>0.031*</td>
<td>0.902</td>
<td>0.039*</td>
</tr>
</tbody>
</table>

Those of statistical significance are marked with asterisks.
Adj, adjusted; BMI, body mass index; OR, odds ratio; POD, post-operative day; s.e., standard error; \( P \) value, probability value.
Predicting durable remission in Cushing’s disease

To identify predictors of recurrence, we performed logistic regression analysis after adjusting for age, BMI, gender and ethnicity. Morning (06:00 h) POD-1 (P=0.002), noon (12:00 h) POD-1 (P=0.040) and evening (18:00 h) POD-1 (P=0.028) cortisol were significantly associated with recurrence (Table 1). Normalized early post-operative values, accurate predictors of early non-remission (30), were analyzed for their potential to predict long-term recurrence. Logistic regression analysis revealed a significant difference between the durable remission and recurrence groups (P=0.026) (Table 1).

Area under the receiver-operating characteristic curve (AUROC) was used to assess the accuracy of association between post-operative cortisol levels and recurrence. Serum cortisol at 06:00 h POD-1 and 18:00 h POD-3 yielded the highest ROC 0.84, P<0.001; 0.90, P<0.023, respectively. NEPV and serum cortisol levels throughout POD-1 and POD-3 remained significant predictors of recurrence (Table 2). Sensitivity and specificity analysis identified a cutoff of <3.3 µg/dL for serum cortisol at 06:00 h POD-1. This achieved a sensitivity of 100%, specificity of 59% and NPV of 1.0 in predicting durable remission. Applying the cutoff of <3.3 µg/dL to 06:00 h POD-1, revealed a significant difference in recurrence rates. There were no observed recurrences in patients whose serum cortisol values reached <3.3 µg/dL by 06:00 h on POD1 (n=55). Patients with values above 3.3 µg/dL (n=64) recurred on an average of 12 months after TSS (P=0.02) (Fig. 2). Furthermore, a cutoff of >18.5 µg/dL for serum cortisol at 06:00 h POD-3 achieved a specificity of 98.6%, sensitivity of 14% and PPV of 0.92 in predicting recurrence (despite nadir ≤5 µg/dL at other time points).

Further AUROC analyses performed to assess accuracy of association between time to reach post-operative cortisol nadir ≤5 µg/dL and remission yielded a ROC of 0.71, P=0.001 (Table 2). Applying a cutoff of 15 h to reach cortisol nadir ≤5 µg/dL achieved a sensitivity of 95%, specificity of 21% NPV 0.98 and PPV 0.10 in predicting durable remission. Association between time to reach

**Table 2** Comparison of post-operative serum cortisol in patients achieving early remission by POD-10. Results of AUROC analyses with recurrence as the reference variable. Remission was defined as cortisol nadir ≤5 µg/dL. Recurrence was defined by biochemical hormone levels, clinical stigmata or medication requirement.

<table>
<thead>
<tr>
<th>Cortisol</th>
<th>AUROC</th>
<th>95% CI</th>
<th>s.d.</th>
<th>n</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>POD-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>00:00 h</td>
<td>0.775</td>
<td>0.64, 0.91</td>
<td>0.067</td>
<td>94</td>
<td>0.010**</td>
</tr>
<tr>
<td>06:00 h</td>
<td>0.839</td>
<td>0.74, 0.94</td>
<td>0.052</td>
<td>119</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>12:00 h</td>
<td>0.761</td>
<td>0.63, 0.89</td>
<td>0.068</td>
<td>103</td>
<td>0.015*</td>
</tr>
<tr>
<td>18:00 h</td>
<td>0.724</td>
<td>0.52, 0.93</td>
<td>0.105</td>
<td>98</td>
<td>0.039*</td>
</tr>
<tr>
<td>POD-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>06:00 h</td>
<td>0.742</td>
<td>0.63, 0.85</td>
<td>0.056</td>
<td>228</td>
<td>&lt;0.001***</td>
</tr>
<tr>
<td>12:00 h</td>
<td>0.753</td>
<td>0.53, 0.97</td>
<td>0.111</td>
<td>52</td>
<td>0.044*</td>
</tr>
<tr>
<td>18:00 h</td>
<td>0.897</td>
<td>0.77, 1.03</td>
<td>0.055</td>
<td>42</td>
<td>0.023*</td>
</tr>
<tr>
<td>NEPV</td>
<td>0.832</td>
<td>0.72, 0.94</td>
<td>0.055</td>
<td>65</td>
<td>0.007**</td>
</tr>
<tr>
<td>Nadir</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5 µg/dL</td>
<td>0.714</td>
<td>0.60, 0.83</td>
<td>0.058</td>
<td>241</td>
<td>0.001***</td>
</tr>
<tr>
<td>≤2 µg/dL</td>
<td>0.661</td>
<td>0.51, 0.80</td>
<td>0.073</td>
<td>222</td>
<td>0.050*</td>
</tr>
</tbody>
</table>

AUROC, area under the receiver-operating curve; CI, confidence interval; NEPV, normalized early post-operative value; POD, post-operative day; P value, probability value; *P<0.05; **P<0.01; ***P<0.001.
Discussion

Identifying predictors of recurrence after resection of ACTH-secreting pituitary adenomas presents a significant clinical challenge. Transsphenoidal surgery, which has the ability to provide rapid symptom relief, effectively moderates the risk of permanent organ damage resulting from hormonal excess (1, 6, 29). Post-operative biochemical markers, therefore, define immediate surgical outcomes (4, 6, 9, 10, 22, 25, 27, 33, 38, 43, 44, 45). The reported remission rates vary widely, ranging from 65 to 97% and may depend on surgical expertise and case volume (2, 3, 4, 5, 6, 7, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27). In recent times, the need for clear criteria defining early biochemical remission has been recognized, in order to better standardize treatment effects in this patient group (5, 46). Furthermore, in a subset of patients who do achieve early post-operative biochemical remission, subsequent recurrence of hypercortisolemia on long-term follow-up has been documented (4, 5, 6, 12, 15, 16, 18, 19, 20, 21, 29, 47).

In our retrospective review of 291 patients treated at a single center, 87% and 79% of patients achieved early hypocortisolemia, ≤5μg/dL and ≤2μg/dL, respectively. Lindsay and coworkers, in a review of 331 patients, have previously reported concordant rates of hypocortisolemia at 98% and 87% for serum cortisol ≤5μg/dL and ≤2μg/dL, respectively (27). However, while their group found no significant difference in recurrence rates between the respective nadir cortisol levels, we were able to demonstrate a significantly higher recurrence rate in patients who did not achieve cortisol nadir <2μg/dL. We suspect that we were able to detect a difference due to the availability of early (<42h) post-operative serum cortisol values. As hypothesized by Monteith and coworkers, this finding suggests that the rate of cortisol decline, and nadir cortisol level, may be associated with completeness of adenoma resection and thereby predict long-term outcomes in patients with CD (12). This hypothesis is also supported by occurrence of same-site recurrence in patients with prior remission from CD (48).

Post-operative hypocortisolemia following ACTH-secreting adenoma resection is thought to be due to chronic suppression of non-adenomatous pituitary corticotrophs in the setting of endogenous hypercortisolemia (9, 49, 50). However, observed differences in serum cortisol and ACTH levels following total hypophysectomy vs adenomectomy suggest some preserved corticotroph secretory function in the normal gland (12). This preserved response was utilized by Asuzu and coworkers to detect a stress-response induced in the immediate post-operative period (30, 51). Therefore, identification of optimal time points for recording serum cortisol is necessary to differentiate the contributions of normal gland and residual tumor. We found that normalized early post-operative cortisol, an effective marker of early remission (30), did not significantly predict long-term recurrence in our patient cohort. Therefore, same-day post-operative serum cortisol values may not be useful for the prediction of eventual recurrence.

We then analyzed post-operative serum cortisol levels to formulate a predictive model for risk of recurrence based on the magnitude and slope of hypocortisolemia. Achievement of nadir cortisol <2μg/dL or <5μg/dL between 12h and five days post-operatively has previously been well documented to be a reliable marker of early remission (25, 31, 52, 53). However, profound post-operative hypocortisolemia has been reported to
have very poor accuracy in predicting durable remission (27, 54, 55, 56). In our cohort, however, 06:00-h POD-1 cortisol <3.3 µg/dL was able to predict durable remission with a sensitivity of 100%. Additionally, 06:00-h POD-3 cortisol >18.6 µg/dL demonstrated 99% specificity as a predictor of recurrence. Prior studies that tested the predictive ability of profound hypocortisolemia or undetectable serum cortisol had serum cortisols drawn more than 3 post-operative days (27, 54, 55, 56). We found that unlike Lindsay and coworkers who obtained cortisol levels on post-operative days 3–5 (27), many patients (n = 127) in the current cohort had earlier (starting approximately 3–6 h post-operatively) laboratory values available. We suspected that the slope of cortisol decline in the post-operative period is critical to determining the likelihood of the presence of microscopic residual tumor remnant. Therefore, we believe that inclusion of early post-operative (<42 h) serum cortisols were critical to improve the predictive accuracy for durable remission. In patients with available early serum cortisol values, and eventual durable remission, hypocortisolemia ≤5 µg/dL was achieved within 15 h (Fig. 1D).

Based on the findings from descriptive analyses, we performed AUROC analyses to generate clinically useful predictive tools. In our model, we assessed whether the slope of fall in serum cortisol could predict durable remission. In our model, hypocortisolemia ≤5 µg/dL by 15 h had 97% sensitivity and an NPV of 0.98 for durable remission. Similarly, in our model, a lower serum cortisol level of ≤2 µg/dL could be achieved by a later time-point of 21 h to improve the sensitivity to 100% and NPV to 1.0. Our findings suggest that early post-operative serum cortisol testing may have a role in predicting long-term outcomes following TSS for CD.

Although the data in this study was drawn from a large cohort of patients with CD, its quality is limited by the retrospective study design. Cortisol laboratory values in the first 42 post-operative hours were missing from a number of patients, who were excluded from further analysis. Semi-autonomous cortisol production due to adrenal nodule formation can severely inhibit correct application of these findings (57). Furthermore, our mean 11-month follow-up period is unlikely to reflect the biochemical characteristics of all patients who experienced long-term recurrence, known to occur up to decades post-operatively. A median time to recurrence of 12 months in the subset of patients with 06:00-h POD-1 cortisol >3.3 µg/dL, highlights this. While surgical technique, surgeon expertise and volume of cases can affect outcomes (1), all included patients underwent surgery at a single center.

Conclusions

In our cohort of patients with CD, the slope in serum cortisol decline in the immediate post-operative period acted as a biochemical marker of recurrence. We found that achievement of hypocortisolemia ≤5 µg/dL by 15 h or ≤2 µg/dL by 21 h appeared to be an accurate predictor of durable remission in the intermediate term. Such a clinical prediction tool may have significant utility in the management of CD. Further validation of its accuracy in a multi-center prospective study with longer-term follow-up is warranted.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this study.

Funding

This work was supported by National Institutes of Health Intramural Grant Z1A NS003150-01 awarded to Prashant Chittiboina. This work was supported by the Intramural Research Programs of the National Institute of Neurological Diseases and Stroke, and Eunice Kennedy Shriver National Institute for Child Health and Human Development, Bethesda, MD.

Author contribution statement

Data collection: S B, M L, S S, L N, C A S, R R, P C; data analysis: N I, G C, D A, P C; manuscript drafting: N I, G C, P C; critical review of manuscript: all authors; study supervision: P C.

Acknowledgements

The authors express gratitude to and recognize the foundational insights for this work from Dr Edward H Oldfield. Dr Oldfield expired earlier this year and was not able to critically review the final version of this manuscript.

References

5 Czepielewski MA, Rollin GAFS, Casagrande A & Ferreira NP. Criteria of cure and remission in Cushing’s disease: an update. Arquivos
10 Veldhuis JD, Iranmanesh A, Johnson ML & Lizarralde G. Twenty-four-hour rhythms in plasma concentrations of adrenocortical hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. Journal of Clinical Endocrinology and Metabolism 1990 71 1616–1623. (https://doi.org/10.1210/jcem-71-6-1616)
Predicting durable remission in Cushing’s disease

N Ironside and others

Clinical Study

178:3

Predicting durable remission in Cushing’s disease

www.eje-online.org

Clinical Study

with pituitary adenomas treated with transsphenoidal surgery. Term significance of microscopic dural invasion in 354 patients with pituitary tumors.

Doppman J, Nieman LK, Grant W, Clinical M, Branch DE et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors.

Doppman J & Nieman LK. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast T1-weighted imaging.


Welch BL. The generalisation of student’s problems when several different population variances are involved. Biometrika 1947; 34:28–35.


Imaki T, Tushima T, Hizuka N, Odagiri E, Murata Y, Suda T & Takano K. Postoperative plasma cortisol levels predict long-term outcome in patients with Cushing’s disease and determine which patients should be treated with pituitary irradiation after surgery. Endocrine Journal 2001; 48:53–62. [https://doi.org/10.1507/ endocrj.48.53]
